VULTUS AB (V06) - Total Liabilities
Based on the latest financial reports, VULTUS AB (V06) has total liabilities worth €5.15 Million EUR (≈ $6.02 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of VULTUS AB to track the company's year-over-year net asset growth rate.
VULTUS AB - Total Liabilities Trend (2021–2025)
This chart illustrates how VULTUS AB's total liabilities have evolved over time, based on quarterly financial data. See VULTUS AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
VULTUS AB Competitors by Total Liabilities
The table below lists competitors of VULTUS AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baring Emerging Europe Plc
LSE:BEMO
|
UK | GBX911.00K |
|
QUADRO RESOURCES LTD
F:G4O
|
Germany | €159.80K |
|
ARMATURA S.A.
RO:ARM
|
Romania | RON501.07K |
|
Spectra7 Microsystems Inc
V:SEV
|
Canada | CA$1.29 Million |
|
Goldhills Holding Ltd
V:GHL
|
Canada | CA$583.50K |
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
India | Rs5.86 Billion |
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
USA | $11.35 Million |
|
Universal Ibogaine Inc
V:IBO
|
Canada | CA$3.73 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down VULTUS AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see V06 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VULTUS AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VULTUS AB (2021–2025)
The table below shows the annual total liabilities of VULTUS AB from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.15 Million ≈ $6.02 Million |
+69.34% |
| 2024-12-31 | €3.04 Million ≈ $3.56 Million |
+75.60% |
| 2023-12-31 | €1.73 Million ≈ $2.02 Million |
+12.30% |
| 2022-12-31 | €1.54 Million ≈ $1.80 Million |
-55.47% |
| 2021-12-31 | €3.46 Million ≈ $4.05 Million |
-- |
About VULTUS AB
C100 AB (publ) is public investment firm specializing in early stage and Emerging stage. The Firm prefers to invest in Technology and Life science Sector. The Firm Typically focuses on early-stage biotech platforms, emerging digital health technologies, transformative software solutions for the investments. C100 AB (publ) is based in stockholm, Sweden.